Open AccessP383: USING CF‐DNA AS STARTING MATERIAL FOR MRD STUDIES BY NGS IMPROVES THE SENSITIVITY OF THE METHOD AGAINST CTCS.
Author(s) -
Álvarez SánchezRedondo N.,
Dorado S.,
Martín A.,
Rufián L.,
Garrido V.,
Giménez A.,
Moreno L.,
Heredia Y.,
MartínezLópez J.,
Barrio S.,
Ayala R.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000844420.94019.1a
Subject(s) - minimal residual disease , liquid biopsy , medicine , myeloid leukemia , bone marrow , biomarker , biopsy , myeloid , oncology , circulating tumor cell , pathology , cancer , biology , genetics , metastasis